A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.
Epistemonikos ID: 7b10744f4502e9342120dc705b7f7f9af9dc7a9d
First added on: Dec 20, 2022